DarioHealth Corp.
DRIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 0.62 | 0.75 | 3.38 |
| FCF Yield | -3.66% | -3.17% | -2.39% | -1.18% |
| EV / EBITDA | -21.04 | -17.81 | -36.01 | -58.38 |
| Quality | ||||
| ROIC | -51.15% | -63.95% | -52.14% | -88.03% |
| Gross Margin | 49.06% | 29.40% | 34.91% | 19.32% |
| Cash Conversion Ratio | 0.90 | 0.51 | 0.77 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.75% | -0.26% | 53.97% | 39.48% |
| Free Cash Flow Growth | -24.99% | 36.05% | 4.44% | -183.80% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.13 | 0.38 | 0.49 |
| Interest Coverage | -601.50 | -87.11 | -21.17 | -910.64 |
| Efficiency | ||||
| Inventory Turnover | 2.90 | 2.84 | 2.26 | 2.66 |
| Cash Conversion Cycle | 117.51 | 165.20 | 198.92 | 56.46 |